These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 4200801)

  • 21. Leukemia and the hypercoagulable state. Pathogenic and therapeutic implications.
    Brodsky I
    J Med; 1974; 5(1):38-49. PubMed ID: 4524857
    [No Abstract]   [Full Text] [Related]  

  • 22. [MYELOPROLIFERATIVE DISORDERS].
    MARCIACQ ALTAFULLA
    Arch Med Panamenos; 1963 Aug; 12():149-59. PubMed ID: 14164997
    [No Abstract]   [Full Text] [Related]  

  • 23. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders.
    Eid J; Ebert RF; Gesell MS; Spivak JL
    Proc Natl Acad Sci U S A; 1987 Jan; 84(2):532-6. PubMed ID: 3467372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoiesis in culture.
    Eaves AC; Eaves CJ
    Clin Haematol; 1984 Jun; 13(2):371-91. PubMed ID: 6432390
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue culture of bone marrow. 3. Myelostimulatory factors in serum of patients with myeloproliferative diseases.
    Reisner EH
    Cancer; 1967 Oct; 20(10):1679-88. PubMed ID: 5234302
    [No Abstract]   [Full Text] [Related]  

  • 26. [THE PLACE OF OSTEOMYELOSCLEROSIS AMONG THE MYELOPROLIFERATIVE DISEASES].
    STOBBE H
    Dtsch Gesundheitsw; 1965 Jan; 20():13-20. PubMed ID: 14265017
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnostic considerations in myelofibrosis].
    Dieska D; Gocárová K; Horváth A; Vahancík A
    Bratisl Lek Listy; 1970 Nov; 54(5):637-42. PubMed ID: 5276096
    [No Abstract]   [Full Text] [Related]  

  • 28. [The role and participation of thrombocytes in hemostasis in the myeloproliferative syndrome].
    Zaĭtseva VN
    Vrach Delo; 1971 Jan; (1):72-6. PubMed ID: 5280699
    [No Abstract]   [Full Text] [Related]  

  • 29. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 30. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
    Gowin K; Coakley M; Kosiorek H; Mesa R
    Haematologica; 2016 Oct; 101(10):e405-e406. PubMed ID: 27354022
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical significance of beta-thromboglobulin in patients with high platelet count.
    Fabris F; Randi ML; Casonato A; Dal Bo Zanon R; Bonvicini P; Girolami A
    Acta Haematol; 1984; 71(1):32-8. PubMed ID: 6197855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 34. [HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
    VON KNORRING
    Nord Med; 1964 Dec; 72():1443-6. PubMed ID: 14211013
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum erythropoietin (ESF) levels and erythroid progenitors (CFU-Es) of patients with chronic myeloproliferative disorders.
    Fukushima Y; Miura I; Takahashi T; Fukuda M; Yoshida K; Yamaguchi A; Miura AB
    Tohoku J Exp Med; 1984 Apr; 142(4):399-407. PubMed ID: 6588639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders.
    Hasselbalch H; Clemmensen I
    Scand J Clin Lab Invest; 1987 Sep; 47(5):429-33. PubMed ID: 3477850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The spectrum of myeloproliferative disorders.
    Gilbert HS
    Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hemostasis disorders with reduced activity of the von Willebrand factor in myeloproliferative syndromes].
    Leupin L; Beck EA; Furlan M; Bucher U
    Schweiz Med Wochenschr; 1983 May; 113(19):713-6. PubMed ID: 6603016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Blood coagulation and fibrinolysis in chronic myeloproliferative syndromes].
    Takahashi K; Shibata A
    Rinsho Ketsueki; 1980 May; 21(5):577-86. PubMed ID: 6997548
    [No Abstract]   [Full Text] [Related]  

  • 40. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.